论文部分内容阅读
目的:研究尼美舒利与阿霉素联合应用对骨肉瘤MG-63细胞的作用及机理。方法:MTT法检测细胞的增殖,衰老相关性β-半乳糖苷酶(SAβ-Gal)染色检测细胞衰老,流式细胞仪测定细胞周期和凋亡,透射电镜显示MG-63细胞的形态变化。结果:当阿霉素浓度固定在0.75mg/L时,与低浓度尼美舒利(25-200μmol/L)结合治疗细胞阻滞MG-63细胞于G2/M期及凋亡,细胞生长抑制呈浓度依赖性增高,与高浓度尼美舒利(400μmol/L)结合治疗细胞阻滞于G1/S期和衰老样生长,蛋白分析表明:bax和P21蛋白表达随尼美舒利浓度增加表达上调,而bcl-2、Cyclin E、C-myc和CDK2蛋白表达下调。结论:联合用药发挥相加作用,为临床联合用药提供了理论依据。
Objective: To study the effect and mechanism of nimesulide combined with adriamycin on osteosarcoma MG-63 cells. Methods: Cell proliferation was detected by MTT assay. Cell senescence was detected by aging-related β-galactosidase (SAβ-Gal) staining. Cell cycle and apoptosis were determined by flow cytometry. Transmission electron microscopy was used to detect the morphological changes of MG-63 cells. Results: When doxorubicin was fixed at 0.75mg / L, MG-63 cells were treated with low concentrations of nimesulide (25-200μmol / L) for G2 / M and apoptosis, cell growth inhibition In a concentration-dependent manner, combined with high concentrations of nimesulide (400μmol / L) treatment of cell arrest in the G1 / S phase and senescent-like growth, protein analysis showed that: bax and P21 protein expression increased with nimesulide concentration But downregulated the expressions of bcl-2, Cyclin E, C-myc and CDK2. Conclusion: The combination of drugs play an additive role, providing a theoretical basis for clinical combination therapy.